Carboplatin and mirvetuximab for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV ovarian, fallopian tube, or primary peritoneal cancer (high-grade serous type).
- A biopsy shows that at least 75% of your cancer cells have the FRα protein (tested in the lab).
- You have not had chemotherapy, radiation, or other cancer treatment for this disease before (except one dose of carboplatin is allowed).
- You are able to perform daily activities (ECOG score 0, 1, or 2).
- You do not have certain eye conditions or lung disease (interstitial lung disease).
- You have not had another cancer in the last 3 years (except for minor skin or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.